Literature DB >> 17401650

Effects of chronic haloperidol and/or clozapine on oxidative stress parameters in rat brain.

Fabiano R Agostinho1, Luciano K Jornada, Nadja Schröder, Rafael Roesler, Felipe Dal-Pizzol, João Quevedo.   

Abstract

Decreased antioxidant activity is considered as one of the causes of tardive dyskinesia in schizophrenic patients in a prolonged neuroleptic treatment course. Haloperidol (HAL) has been hypothesized to increase oxidative stress, while clozapine (CLO) would produce less oxidative damage. The objective was to determine whether CLO for 28 days could reverse or attenuate HAL-induced oxidative damage in animals previously treated with HAL for 28 days. HAL significantly increased thiobarbituric acid reactive substances levels in the cortex (CX) and striatum and increased protein carbonyls in hippocampus (HP) and CX and this was not attenuated by CLO treatment. In the total radical trapping antioxidant parameter assay there was a decrease in the HP total antioxidant potential induced by HAL and by treatment with HAL + CLO. Our findings demonstrated that the atypical antipsychotic CLO could not revert oxidative damage caused by HAL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401650     DOI: 10.1007/s11064-007-9311-3

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  44 in total

Review 1.  Tardive dyskinesia: review of treatments past, present, and future.

Authors:  S Gupta; D Mosnik; D W Black; S Berry; P S Masand
Journal:  Ann Clin Psychiatry       Date:  1999-12       Impact factor: 1.567

2.  In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic.

Authors:  H Yokoyama; N Kasai; Y Ueda; R Niwa; R Konaka; N Mori; N Tsuchihashi; T Matsue; H Ohya-Nishiguchi; H Kamada
Journal:  Free Radic Biol Med       Date:  1998-04       Impact factor: 7.376

3.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

Review 4.  A "radical" view of cerebral ischemic injury.

Authors:  J W Phillis
Journal:  Prog Neurobiol       Date:  1994-03       Impact factor: 11.685

Review 5.  The treatment of tardive dyskinesia--a systematic review and meta-analysis.

Authors:  K V Soares; J J McGrath
Journal:  Schizophr Res       Date:  1999-08-23       Impact factor: 4.939

Review 6.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

7.  Tardive dystonia. Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients.

Authors:  M Raja
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

8.  Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.

Authors:  O A Andreassen; R J Ferrante; T O Aamo; M F Beal; H A Jørgensen
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 9.  Oxidative stress, glutamate, and neurodegenerative disorders.

Authors:  J T Coyle; P Puttfarcken
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

10.  Oxidative stress and thiol modification induced by chronic administration of haloperidol.

Authors:  B R Shivakumar; V Ravindranath
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

View more
  1 in total

1.  Clozapine linked to nanocapsules minimizes tissue and oxidative damage to biomolecules lipids, proteins and DNA in brain of rats Wistar.

Authors:  Angélica Aparecida da Costa Güllich; Ritiéle Pinto Coelho; Bruna Cocco Pilar; Deise Jaqueline Ströher; Leandro Alex Sander Leal Galarça; Simone Machado Vieira; Jacqueline da Costa Escobar Piccoli; Sandra Elisa Haas; Vanusa Manfredini
Journal:  Metab Brain Dis       Date:  2014-10-09       Impact factor: 3.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.